Table 2 Comparative antiviral activity of IFNα2b fusion proteins.

From: Development of latent Interferon alpha 2b as a safe therapeutic for treatment of Hepatitis C virus infection

Fusion protein

EC50 (pg/ml)

IU/ml

Specific activity (U/mg)

Percentage activity relative to IFNα2b

Latent IFNα2b-NS3-LAP

4000

2.1 × 107

5.20 × 105

0.2%

Pre-activated IFNα2b-NS3-LAP

22.22

1.3 × 107

9.36 × 107

36%

Real time activated IFNα2b-NS3-LAP

25

2.0 × 107

8.32 × 107

32%

Latent LAP-NS3-IFNα2b

5000

2.7 × 107

4.16 × 105

0.16%

Pre-activated LAP-NS3-IFNα2b

23.52

1.4 × 107

8.84 × 107

34%

Real time activated LAP-NS3-IFNα2b

26.66

1.3 × 107

1.3 × 107

30%

IFNα2b (standard)

8.0

 

2.6 × 108

100%